NRX Pharmaceuticals (NRXP) Convertible Debt (2024)

NRX Pharmaceuticals' (NRXP) quarterly Convertible Debt came in at $5.0 million in Q4 2024, up 67.87% on a QoQ basis from $3.0 million in Q3 2024.

NRX Pharmaceuticals (NRXP) Convertible Debt (2024) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 1 years of Convertible Debt data on file, last reported at $5.0 million in Q4 2024.

On a quarterly basis, Convertible Debt changed N/A year-over-year to $5.0 million in Q4 2024; TTM through Dec 2024 was $5.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $5.0 million, changed N/A from the prior year.
Convertible Debt for Q4 2024 stood at $5.0 million, up from $3.0 million in the prior quarter.
Over the last five years, Convertible Debt for NRXP reached as high as $7.7 million in Q2 2024 and fell as low as $3.0 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	NRX Pharmaceuticals	137.57 Mn	130.87 Mn	437,000.00

Download Data